University of Cagliari
open
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
Caocci, Giovanni
;Mulas, Olga;Costa, Alessandro;Galitzia, Andrea;Barabino, Luca;Greco, Marianna;La Nasa, Giorgio
2021-01-01
Abstract
Patients with Myelobrosis (MF) are considered fragile and thus eligible in Italy for COVID-19 BNT162b2 mRNA vaccination. According to the International Prognostic Scoring System (IPSS), patients with intermediate and high MF, may receive clinical benets from ruxolitinib, the rst approved JAK1/JAK2 inhibitor. Given the potent anti-in ammatory properties of ruxolitinib against immunocompetent cells, we previously reported a lower but non-statistically absolute IgG anti-Spike humoral response in vaccinated MF patients treated with ruxolitinib. In the present report we extended the cohort of MF patients.
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| PDF 2 abstracts 1-s2.0-S0006497121045201-main.pdf open access
Type: versione editoriale
Size 389.59 kB
Format Adobe PDF
|
389.59 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.